FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116162912> ?p ?o ?g. }

• W2116162912 abstract "Background Non‐randomised data have shown a link between hyperuricaemia and the progression or development of chronic kidney disease (CKD). If this is correct, urate lowering therapy might form an important part of chronic kidney disease care, reducing risks for cardiovascular outcomes and end‐stage kidney disease. Objectives This review aims to study the benefits and harms of uric acid lowering therapy on the progression of CKD and other cardiovascular endpoints. Search methods We searched the Cochrane Kidney and Transplant Specialised Register to 20 July 2017 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. Selection criteria All randomised controlled trials testing primary urate lowering therapy in patients with or without CKD. Data collection and analysis Two authors independently assessed study quality and extracted data. Statistical analyses were performed using a random effects model and results expressed as risk ratio (RR) with 95% confidence intervals (CI) for dichotomous outcomes or mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) if different scales were used. Main results Twelve studies (1187 participants) were included in the review. Risk of bias was unclear for the majority of domains in each study. Uric acid lowering therapy may make little or no difference in death at six months (2 studies, 498 participants: RR 1.66, 95% CI 0.61 to 4.48) or two years (2 studies, 220 participants): RR 0.13, 95% CI 0.02 to 1.06) (low certainty evidence). Uric acid lowering therapy may make little of no difference (low certainty evidence) in the incidence of ESKD at one or two years. Kidney function may be improved by uric acid lowering therapy at one year with a reduction in serum creatinine (2 studies, 83 participants: MD ‐73.35 µmol/L, 95% CI ‐107.28 to ‐39.41) and a rise in eGFR (1 study, 113 participants: MD 5.50 mL/min/1.73 m2, 95% CI 0.59 to 10.41). However it probably makes little or no difference to eGFR at two years (2 studies, 164 participants: MD 4.00 mL/min, 95% CI ‐3.28 to 11.28). Uric acid lowering therapy reduced uric acid levels at all time points (3, 4, 6, 12 and 24 months) (high certainty evidence). There is insufficient evidence to support an effect on blood pressure, proteinuria or other cardiovascular markers by uric acid lowering therapy. It should be noted that the apparent benefits of treatment were not apparent at all time points, introducing the potential for bias. Authors' conclusions There is limited data which suggests uric acid lowering therapy may prevent progression of chronic kidney disease but the conclusion is very uncertain. Benefits were not observed at all time points and study quality was generally low. Larger studies are required to study the effect of uric acid lowering therapy on CKD progression. Three ongoing studies will hopefully provide much needed high quality data." @default.
• W2116162912 created "2016-06-24" @default.
• W2116162912 creator A5015378680 @default.
• W2116162912 creator A5030905506 @default.
• W2116162912 creator A5040367797 @default.
• W2116162912 date "2017-10-30" @default.
• W2116162912 modified "2023-09-24" @default.
• W2116162912 title "Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease" @default.
• W2116162912 cites W1414418298 @default.
• W2116162912 cites W1493873719 @default.
• W2116162912 cites W1499216809 @default.
• W2116162912 cites W1561987315 @default.
• W2116162912 cites W1570583414 @default.
• W2116162912 cites W1955399352 @default.
• W2116162912 cites W1979293107 @default.
• W2116162912 cites W1990507119 @default.
• W2116162912 cites W1997352207 @default.
• W2116162912 cites W2020498771 @default.
• W2116162912 cites W2025125071 @default.
• W2116162912 cites W2030058610 @default.
• W2116162912 cites W2032779275 @default.
• W2116162912 cites W2034398577 @default.
• W2116162912 cites W2036026458 @default.
• W2116162912 cites W2043819138 @default.
• W2116162912 cites W2045516356 @default.
• W2116162912 cites W2051016191 @default.
• W2116162912 cites W2051544630 @default.
• W2116162912 cites W2054392576 @default.
• W2116162912 cites W2078718265 @default.
• W2116162912 cites W2088223659 @default.
• W2116162912 cites W2094392313 @default.
• W2116162912 cites W2104681259 @default.
• W2116162912 cites W2106403351 @default.
• W2116162912 cites W2111255580 @default.
• W2116162912 cites W2120138329 @default.
• W2116162912 cites W2122983268 @default.
• W2116162912 cites W2125435699 @default.
• W2116162912 cites W2125550109 @default.
• W2116162912 cites W2132895884 @default.
• W2116162912 cites W2137214955 @default.
• W2116162912 cites W2146378769 @default.
• W2116162912 cites W2149054665 @default.
• W2116162912 cites W2155024437 @default.
• W2116162912 cites W2162688873 @default.
• W2116162912 cites W2164427101 @default.
• W2116162912 cites W2165010366 @default.
• W2116162912 cites W4211214771 @default.
• W2116162912 cites W44590008 @default.
• W2116162912 doi "https://doi.org/10.1002/14651858.cd009460.pub2" @default.
• W2116162912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6485406" @default.
• W2116162912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29084343" @default.
• W2116162912 hasPublicationYear "2017" @default.
• W2116162912 type Work @default.
• W2116162912 sameAs 2116162912 @default.
• W2116162912 citedByCount "38" @default.
• W2116162912 countsByYear W21161629122015 @default.
• W2116162912 countsByYear W21161629122018 @default.
• W2116162912 countsByYear W21161629122019 @default.
• W2116162912 countsByYear W21161629122020 @default.
• W2116162912 countsByYear W21161629122021 @default.
• W2116162912 countsByYear W21161629122022 @default.
• W2116162912 countsByYear W21161629122023 @default.
• W2116162912 crossrefType "journal-article" @default.
• W2116162912 hasAuthorship W2116162912A5015378680 @default.
• W2116162912 hasAuthorship W2116162912A5030905506 @default.
• W2116162912 hasAuthorship W2116162912A5040367797 @default.
• W2116162912 hasBestOaLocation W21161629122 @default.
• W2116162912 hasConcept C126322002 @default.
• W2116162912 hasConcept C168563851 @default.
• W2116162912 hasConcept C17744445 @default.
• W2116162912 hasConcept C177713679 @default.
• W2116162912 hasConcept C1862650 @default.
• W2116162912 hasConcept C199539241 @default.
• W2116162912 hasConcept C2778653478 @default.
• W2116162912 hasConcept C2779473830 @default.
• W2116162912 hasConcept C2779541074 @default.
• W2116162912 hasConcept C2779881121 @default.
• W2116162912 hasConcept C44249647 @default.
• W2116162912 hasConcept C535046627 @default.
• W2116162912 hasConcept C71924100 @default.
• W2116162912 hasConcept C82789193 @default.
• W2116162912 hasConcept C95190672 @default.
• W2116162912 hasConceptScore W2116162912C126322002 @default.
• W2116162912 hasConceptScore W2116162912C168563851 @default.
• W2116162912 hasConceptScore W2116162912C17744445 @default.
• W2116162912 hasConceptScore W2116162912C177713679 @default.
• W2116162912 hasConceptScore W2116162912C1862650 @default.
• W2116162912 hasConceptScore W2116162912C199539241 @default.
• W2116162912 hasConceptScore W2116162912C2778653478 @default.
• W2116162912 hasConceptScore W2116162912C2779473830 @default.
• W2116162912 hasConceptScore W2116162912C2779541074 @default.
• W2116162912 hasConceptScore W2116162912C2779881121 @default.
• W2116162912 hasConceptScore W2116162912C44249647 @default.
• W2116162912 hasConceptScore W2116162912C535046627 @default.
• W2116162912 hasConceptScore W2116162912C71924100 @default.
• W2116162912 hasConceptScore W2116162912C82789193 @default.
• W2116162912 hasConceptScore W2116162912C95190672 @default.
• W2116162912 hasIssue "10" @default.
• W2116162912 hasLocation W21161629121 @default.
• W2116162912 hasLocation W21161629122 @default.

• next